ARDS
GBS
Myasthenia Gravis
ABG
&
PFT
Management
&
Failure
100

This type of lung disorder is caused by ARDS

Restrictive 

100

This type of paralysis occurs in GBS

Flaccid 

100

This is the hallmark symptom of myasthenia gravis

Fluctuating muscle weakness 

100

Early ARDS ABG shows this acid-base disorder

Respiratory Alkalosis 

100

This therapy is First-Line for GBS

Intravenous Immunoglobulin or Plasmapheresis 

200

In ARDS, loss of this leads to alveolar collapse 

Surfactant 

200

GBS paralysis progresses in this direction 

Ascending 

200

Muscle strength in MG improves after this 

Rest

200

Severe ARDS ABG shows this disorder 

Respiratory Acidosis 

200

This drug is commonly used to treat MG

Pyridostigmine 

300

This membrane lines the alveoli in ARDS

Hyaline Membrane 

300

This commonly occurs 1-4 weeks before GBS onset 

Infection 

300

These antibodies cause MG

Acetylcholine receptor antibodies 

300

MG and GBS both show this PFT Pattern 

Restrictive 

300

Severe ARDS patients require this support 

Mechanical Ventilation 

400

ARDS Chest X-Ray shows this diffuse pattern

Ground-Glass Opacity

400

These reflexes are absent in GBS

Deep tendon reflexes 

400

These muscles are affected first in MG

Eye/Face Muscles 

400

This value decreases in neuromuscular respiratory failure 

FVC

400

This ventilation strategy uses 6-8 mL/kg tidal volumes 

Low Tidal Volume Ventilation 

500

A PaO2/FiO2 ratio at or below this value defines severe ARDS

100

500

This percentage of GBS patients develop Ventilatory failure

10 to 30%

500

This condition occurs when respiratory muscles fail in MG

Myasthenic Crisis

500

This pressure measurement decreases in respiratory muscles weakness

Maximum Inspiratory Pressure 

500

This FVC value indicates impending ventilatory failure

20 mL/kg